Construction of a prognostic signature for breast cancer based on genes involved in unsaturated fatty acid biosynthesis.

IF 1.5 4区 医学 Q4 ONCOLOGY
Translational cancer research Pub Date : 2025-02-28 Epub Date: 2025-02-24 DOI:10.21037/tcr-24-1668
Hua Meng, Shuangyi Zhang, Min Ling, Yuanyuan Hu, Xiaohong Xie
{"title":"Construction of a prognostic signature for breast cancer based on genes involved in unsaturated fatty acid biosynthesis.","authors":"Hua Meng, Shuangyi Zhang, Min Ling, Yuanyuan Hu, Xiaohong Xie","doi":"10.21037/tcr-24-1668","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The biosynthesis of unsaturated fatty acids (UFAs) has been implicated in the onset and advancement of breast cancer (BC). This study aimed to develop molecular subtypes and prognostic signatures for BC based on UFA-related genes (UFAGs).</p><p><strong>Methods: </strong>This study integrates multi-omics and survival data from public databases to elucidate molecular classifications and risk profiles based on UFAGs. Consensus clustering and Lasso Cox regression methodologies are employed for subtype identification and risk signature development, respectively. Immune microenvironment assessment is conducted using CIBERSORT and ESTIMATE algorithms, while drug sensitivity and response to immunotherapy are evaluated via pRRophetic and TIDE methods. Gene set enrichment analysis augments signature characterization, followed by nomogram construction and validation.</p><p><strong>Results: </strong>We successfully identified two distinct BC molecular subtypes with significantly different prognoses utilizing UFAGs correlated with outcomes. A prognostic signature comprising three UFAGs [acetyl-CoA acyltransferase 1 (<i>ACAA1</i>), acyl-CoA thioesterase 2 (<i>ACOT2</i>), and ELOVL fatty acid elongase 2 (<i>ELOVL2</i>)] is developed, stratifying patients into high- and low-risk groups exhibiting divergent outcomes, clinicopathological traits, gene expression patterns, immune infiltration profiles, therapeutic susceptibility, and immunotherapy responses. The signature demonstrates robust prognostic performance in both training and validation cohorts, emerging as an independent predictor alongside age, which is integrated into a nomogram. Decision curve analysis highlights the nomogram's superiority over other factors in prognosis prediction. Calibration plots and receiver operating characteristic curves affirm its excellent performance in BC prognosis assessment.</p><p><strong>Conclusions: </strong>Expression profiles of UFAGs are associated with BC prognosis, enabling the creation of a risk signature with implications for understanding the molecular mechanisms underlying BC progression.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"1190-1204"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912055/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1668","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The biosynthesis of unsaturated fatty acids (UFAs) has been implicated in the onset and advancement of breast cancer (BC). This study aimed to develop molecular subtypes and prognostic signatures for BC based on UFA-related genes (UFAGs).

Methods: This study integrates multi-omics and survival data from public databases to elucidate molecular classifications and risk profiles based on UFAGs. Consensus clustering and Lasso Cox regression methodologies are employed for subtype identification and risk signature development, respectively. Immune microenvironment assessment is conducted using CIBERSORT and ESTIMATE algorithms, while drug sensitivity and response to immunotherapy are evaluated via pRRophetic and TIDE methods. Gene set enrichment analysis augments signature characterization, followed by nomogram construction and validation.

Results: We successfully identified two distinct BC molecular subtypes with significantly different prognoses utilizing UFAGs correlated with outcomes. A prognostic signature comprising three UFAGs [acetyl-CoA acyltransferase 1 (ACAA1), acyl-CoA thioesterase 2 (ACOT2), and ELOVL fatty acid elongase 2 (ELOVL2)] is developed, stratifying patients into high- and low-risk groups exhibiting divergent outcomes, clinicopathological traits, gene expression patterns, immune infiltration profiles, therapeutic susceptibility, and immunotherapy responses. The signature demonstrates robust prognostic performance in both training and validation cohorts, emerging as an independent predictor alongside age, which is integrated into a nomogram. Decision curve analysis highlights the nomogram's superiority over other factors in prognosis prediction. Calibration plots and receiver operating characteristic curves affirm its excellent performance in BC prognosis assessment.

Conclusions: Expression profiles of UFAGs are associated with BC prognosis, enabling the creation of a risk signature with implications for understanding the molecular mechanisms underlying BC progression.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
252
期刊介绍: Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信